Hovione Acquires ExtremoChem for Enhanced Biopharmaceutical Stabilization and Delivery

Hovione has acquired ExtremoChem Lda, a start-up company with a portfolio of rare sugars, synthetic analogues of the natural molecules found in extremoph...

November 21, 2023 | Tuesday | News
Bogota's Biopharma Breakthrough: A Strategic Dialogue with Isabella Muñoz, Executive Director of Invest In Bogota

In an exclusive interview with BioPharma BoardRoom, Isabella Muñoz, Executive Director of Invest In Bogota, shares insights into how Bogota has posi...

November 17, 2023 | Friday | Interview
Hovione Acquires ExtremoChem for Biopharmaceutical Stabilization and Delivery

Hovione has acquired ExtremoChem Lda, a start-up company with a portfolio of rare sugars, synthetic analogues of the natural molecule...

November 17, 2023 | Friday | News
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program

Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneou...

November 14, 2023 | Tuesday | News
Sandoz Opens Antibiotic Plant in Austria, Biosimilar Center in Germany

Investment of EUR 175 million reaffirms Sandoz commitment to long-term leadership in off-patent medicines New penicillin production process will signifi...

November 13, 2023 | Monday | News
STADA, Alvotech Get Positive CHMP Nod for Europe's First Ustekinumab Biosimilar to Stelara

Positive CHMP opinion for Uzpruvo biosimilar is based on comprehensive package comprising analytical, non-clinical and clinical similarity data, includin...

November 13, 2023 | Monday | News
FDA Prioritizes Bristol Myers Squibb's Breyanzi for CLL/SLL Review

Application based on results from TRANSCEND CLL 004, the first pivotal multicenter trial to show clinical benefit with a CAR T cell therapy in heavil...

November 10, 2023 | Friday | News
Aldeyra Therapeutics and AbbVie Sign Exclusive Option Agreement for Reproxalap License

Under the terms of the option agreement, AbbVie has the option to acquire a co-exclusive license to develop, manufacture, and commercialize reproxalap in t...

November 02, 2023 | Thursday | News
FDA Approves Novartis Cosentyx® as First New Biologic for Hidradenitis Suppurativa in 10 Years

FDA approval based on robust Phase III data in which Cosentyx® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as ea...

November 01, 2023 | Wednesday | News
Quantum Leap Initiates Phase 2 DCIS Platform Trial with Atossa, Havah, and Menarini

Quantum Leap Healthcare Collaborative (QLHC) announces the enrollment launch for the Re-Evaluating Conditions for Active Surveillance Suitability as Treatm...

October 31, 2023 | Tuesday | News
Empowering sustainability: dsm-firmenich’s Imp’Act Card™ shines at CPHI Pharma Awards 2023

The initiative was introduced to translate the traceability, certifications, as well as the environmental and social impact of the company’s ingredie...

October 26, 2023 | Thursday | News
Biogen's Tau-Targeting ASO Promising in Early Alzheimer's Treatment Development

In the Phase 1b study, favorable trends were reported for the high-dose groups on multiple measures of cognition and function. First study of a tau targ...

October 26, 2023 | Thursday | News
LumaCyte Unveils Compact Radiance® Instrument for Biomanufacturing & QC in Advanced Therapy

LumaCyte, a leading innovator in advanced single cell analysis technology and instrumentation, is proud to announce the launch of their newly redesigned fl...

October 25, 2023 | Wednesday | News
Government of Serbia and Ginkgo Bioworks Announce Bioeconomy Collaboration in BIO4 Campus

Under the planned partnership, Ginkgo and the Serbian Ministry of Science, Technological Development and Innovation will work to establish a Startup Accele...

October 23, 2023 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close